New treatment options for acute coronary syndromes

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Complications from atherosclerotic coronary artery disease are the principal cause of death worldwide. Many therapeutic strategies have been developed to reduce the burden of this disease. Systemic antithrombotic therapy, typically with unfractionated heparin, has long been a mainstay in the management of acute coronary syndromes (ACS) despite several limitations, including intravenous administration and unpredictable pharmacokinetics' necessitating frequent monitoring. In recent years, newer agents without these limitations have been developed and evaluated in clinical trials. This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa.

Original languageEnglish (US)
JournalAmerican Journal of Managed Care
Volume12
Issue numberSUPPL. 16
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Acute Coronary Syndrome
Blood Coagulation Factors
Intravenous Administration
Heparin
Coronary Artery Disease
Cause of Death
Therapeutics
Pharmacokinetics
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

New treatment options for acute coronary syndromes. / Campbell, Charles.

In: American Journal of Managed Care, Vol. 12, No. SUPPL. 16, 01.12.2006.

Research output: Contribution to journalArticle

@article{54ef219a4bcd4c7286199860ac774aee,
title = "New treatment options for acute coronary syndromes",
abstract = "Complications from atherosclerotic coronary artery disease are the principal cause of death worldwide. Many therapeutic strategies have been developed to reduce the burden of this disease. Systemic antithrombotic therapy, typically with unfractionated heparin, has long been a mainstay in the management of acute coronary syndromes (ACS) despite several limitations, including intravenous administration and unpredictable pharmacokinetics' necessitating frequent monitoring. In recent years, newer agents without these limitations have been developed and evaluated in clinical trials. This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa.",
author = "Charles Campbell",
year = "2006",
month = "12",
day = "1",
language = "English (US)",
volume = "12",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "SUPPL. 16",

}

TY - JOUR

T1 - New treatment options for acute coronary syndromes

AU - Campbell, Charles

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Complications from atherosclerotic coronary artery disease are the principal cause of death worldwide. Many therapeutic strategies have been developed to reduce the burden of this disease. Systemic antithrombotic therapy, typically with unfractionated heparin, has long been a mainstay in the management of acute coronary syndromes (ACS) despite several limitations, including intravenous administration and unpredictable pharmacokinetics' necessitating frequent monitoring. In recent years, newer agents without these limitations have been developed and evaluated in clinical trials. This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa.

AB - Complications from atherosclerotic coronary artery disease are the principal cause of death worldwide. Many therapeutic strategies have been developed to reduce the burden of this disease. Systemic antithrombotic therapy, typically with unfractionated heparin, has long been a mainstay in the management of acute coronary syndromes (ACS) despite several limitations, including intravenous administration and unpredictable pharmacokinetics' necessitating frequent monitoring. In recent years, newer agents without these limitations have been developed and evaluated in clinical trials. This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa.

UR - http://www.scopus.com/inward/record.url?scp=33845981516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845981516&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - SUPPL. 16

ER -